ArticleMedicine2026
Association between eGDR and the risk of chest pain: A comparative analysis based on NHANES and CHARLS databases.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Insulin resistance is closely associated with various cardiovascular and metabolic diseases. The estimated glucose disposal rate (eGDR), as a convenient assessment indicator of insulin resistance, has been increasingly utilized in recent years for cardiovascular risk prediction. However, studies on the relationship between eGDR and chest pain risk remain relatively scarce. Based on the 2 major databases of National Health and Nutrition Examination Survey (NHANES) and China Health and Retirement Longitudinal Study (CHARLS), this study systematically analyzed the association between eGDR levels and the risk of chest pain and compared the similarities and differences in the results between the 2 populations. We utilized databases from 2 prospective cohorts, NHANES and CHARLS. The eGDR calculation formula was: eGDR = 21.158 - (0.09 × WC) - (3.407 × HTN) - (0.551 × HbA1c). Here, WC represents waist circumference (cm), HTN indicates a history of hypertension (yes = 1, no = 0), and HbA1c denotes glycated hemoglobin (%). Participants were stratified according to eGDR levels into quartiles. A multivariate logistic regression model was employed to assess the association between eGDR and chest pain, with dose-response curves analyzed using restricted cubic spline analysis. In the fully adjusted model, the highest quartile of eGDR in CHARLS showed a trend of reduced risk for chest pain compared to the lowest quartile (odds ratio = 0.86, 95% confidence interval: 0.73-1.01, P = .066), whereas a significant negative correlation was observed in NHANES (odds ratio = 0.54, 95% confidence interval: 0.45-0.65, P < .001). Elevated eGDR (reduced insulin resistance) was significantly associated with a decreased risk of chest pain, suggesting that insulin resistance may be an important potential risk factor for chest pain. This association was consistent in both China and the United States, though the magnitude of the effect varied. This study supports the use of eGDR as a potential biomarker for identifying chest pain risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.